Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 200-209

  Guenther, Monika Katharina ^a   Graab, Ulrike ^a   Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; MAPK; PI3K; Rhabdomyosarcoma

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P110ALPHA; RAS PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; UO 126; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; GENE SILENCING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

APOPTOSIS; MAPK; PI3K; RHABDOMYOSARCOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BUTADIENES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FURANS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR TARGETED THERAPY; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; RAS PROTEINS; RHABDOMYOSARCOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84880506610     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.010     Document Type: Article

References (50)

1. Dagher R., Helman L. Rhabdomyosarcoma: an overview. Oncologist 1999, 4:34-44.
2. Hayes-Jordan A., Andrassy R. Rhabdomyosarcoma in children. Curr. Opin. Pediatr. 2009, 21:373-378.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
5. De Luca A., Maiello M.R., D'Alessio A., Pergameno M., Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 2012, 16(Suppl. 2):S17-27.
6. Katz M., Amit I., Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 2007, 1773:1161-1176.
7. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
8. Fulda S. Modulation of mitochondrial apoptosis by PI3K inhibitors. Mitochondrion 2013, 13:195-198.
9. Martinelli S., McDowell H.P., Vigne S.D., Kokai G., Uccini S., Tartaglia M., Dominici C. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer 2009, 48:975-982.
10. Paulson V., Chandler G., Rakheja D., Galindo R.L., Wilson K., Amatruda J.F., Cameron S. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 2011, 50:397-408.
11. Schaaf G., Hamdi M., Zwijnenburg D., Lakeman A., Geerts D., Versteeg R., Kool M. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res. 2010, 70:762-771.
12. Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 2012, 18:748-757.
13. Taylor J.G.t., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., Yu Y., Chen Q.R., Shah K., Youngblood V., Fang J., Kim S.Y., Yeung C., Helman L.J., Mendoza A., Ngo V., Staudt L.M., Wei J.S., Khanna C., Catchpoole D., Qualman S.J., Hewitt S.M., Merlino G., Chanock S.J., Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 2009, 119:3395-3407.
14. Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas. J. Pathol. 2009, 217:469-482.
15. Petricoin E.F., Espina V., Araujo R.P., Midura B., Yeung C., Wan X., Eichler G.S., Johann D.J., Qualman S., Tsokos M., Krishnan K., Helman L.J., Liotta L.A. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007, 67:3431-3440.
16. Aksamitiene E., Kiyatkin A., Kholodenko B.N. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem. Soc. Trans. 2012, 40:139-146.
17. Castellano E., Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011, 2:261-274.
18. Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2012, 2:311-319.
19. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., Basecke J., Stivala F., Donia M., Fagone P., Malaponte G., Mazzarino M.C., Nicoletti F., Libra M., Maksimovic-Ivanic D., Mijatovic S., Montalto G., Cervello M., Laidler P., Milella M., Tafuri A., Bonati A., Evangelisti C., Cocco L., Martelli A.M., McCubrey J.A. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2:135-164.
20. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
21. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
22. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., Januario T., Savage H., Punnoose E., Truong T., Zhou W., Berry L., Murray L., Amler L., Belvin M., Friedman L.S., Lackner M.R. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 2009, 15:4649-4664.
23. Hoeflich K.P., Merchant M., Orr C., Chan J., Den Otter D., Berry L., Kasman I., Koeppen H., Rice K., Yang N.Y., Engst S., Johnston S., Friedman L.S., Belvin M. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012, 72:210-219.
24. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997, 57:3823-3829.
25. Hacker S., Dittrich A., Mohr A., Schweitzer T., Rutkowski S., Krauss J., Debatin K.M., Fulda S. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009, 28:3097-3110.
26. Chou T.C. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and Antagonism in Chemotherapy 1991, 61-102. Academic Press, San Diego, USA. T.C. Chou (Ed.).
27. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., Dawson T.M., Dawson V.L., El-Deiry W.S., Fulda S., Gottlieb E., Green D.R., Hengartner M.O., Kepp O., Knight R.A., Kumar S., Lipton S.A., Lu X., Madeo F., Malorni W., Mehlen P., Nunez G., Peter M.E., Piacentini M., Rubinsztein D.C., Shi Y., Simon H.U., Vandenabeele P., White E., Yuan J., Zhivotovsky B., Melino G., Kroemer G. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death. Cell Death Differ. 2012, 19(2012):107-120.
28. Normanno N., De Luca A., Maiello M.R., Campiglio M., Napolitano M., Mancino M., Carotenuto A., Viglietto G., Menard S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell Physiol. 2006, 207:420-427.
29. Ventura A.P., Radhakrishnan S., Green A., Rajaram S.K., Allen A.N., O'Briant K., Schummer M., Karlan B., Urban N., Tewari M., Drescher C., Knudsen B.S. Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl. Immunohistochem. Mol. Morphol.: AIMM/Off. Publ. Soc. Appl. Immunohistochem. 2010, 18:499-508.
30. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
31. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9:231-241.
32. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
33. Cen L., Arnoczky K.J., Hsieh F.-C., Lin H.-J., Qualman S.J., Yu S., Xiang H., Lin J. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol. 2007, 20:936-946.
34. Yu C.F., Liu Z.X., Cantley L.G. ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J. Biol. Chem. 2002, 277:19382-19388.
35. Arvisais E., Hou X., Wyatt T.A., Shirasuna K., Bollwein H., Miyamoto A., Hansen T.R., Rueda B.R., Davis J.S. Prostaglandin F2alpha represses IGF-I-stimulated IRS1/phosphatidylinositol-3-kinase/AKT signaling in the corpus luteum: role of ERK and P70 ribosomal S6 kinase. Mol. Endocrinol. 2010, 24:632-643.
36. Wu Y., Chen Z., Ullrich A. EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2. Biol. Chem. 2003, 384:1215-1226.
37. Hayashi H., Tsuchiya Y., Nakayama K., Satoh T., Nishida E. Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling. Genes Cells: Dev. Mol. Cell. Mech. 2008, 13:941-947.
38. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
39. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., Kwiatkowski D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 2003, 112:1223-1233.
40. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166:213-223.
41. Ley R., Balmanno K., Hadfield K., Weston C., Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein. Bim. J. Biol. Chem. 2003, 278:18811-18816.
42. Townsend K.J., Trusty J.L., Traupman M.A., Eastman A., Craig R.W. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene 1998, 17:1223-1234.
43. Kuo M.L., Chuang S.E., Lin M.T., Yang S.Y. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001, 20:677-685.
44. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., Tsang B.K., Cheng J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 2004, 279:5405-5412.
45. Jeong J.C., Kim M.S., Kim T.H., Kim Y.K. Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells. Neurochem. Res. 2009, 34:991-1001.
46. Sheridan C., Brumatti G., Elgendy M., Brunet M., Martin S.J. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 2010, 29:6428-6441.
47. Lin C.L., Tseng H.C., Chen R.F., Chen W.P., Su M.J., Fang K.M., Wu M.L. Intracellular zinc release-activated ERK-dependent GSK-3beta-p53 and Noxa-Mcl-1 signaling are both involved in cardiac ischemic-reperfusion injury. Cell Death Differ. 2011, 18:1651-1663.
48. Bender A., Opel D., Naumann I., Kappler R., Friedman L., von Schweinitz D., Debatin K.M., Fulda S. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 2011, 30:494-503.
49. Opel D., Naumann I., Schneider M., Bertele D., Debatin K.M., Fulda S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin. Cancer Res. 2011, 17:3233-3247.
50. Marklein D., Graab U., Naumann I., Yan T., Ridzewski R., Nitzki F., Rosenberger A., Dittmann K., Wienands J., Wojnowski L., Fulda S., Hahn H. PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells. PLoS ONE 2012, 7:e52898.